The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

We assessed serum CGRP concentrations in forty migraine patients according to the International Classification of Headache Disorders 3rd edition aged 10-55 years with migraines before and after receiving lacosamide 50 mg Bid for 3 months

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kafrelsheikh University
• Treatments: Lacosamide

Criteria

Inclusion Criteria:

• migraine patients according to the International Classification of Headache Disorders 3rd edition aged 10-55 years. our selected patients were naive, they didn't receive any prophylactic therapy for migraine before.

Exclusion Criteria:

• Patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumours, patients with essential tremors, were excluded, as well as patients with major systemic diseases such as malignancy, collagen diseases, liver diseases, renal diseases and cardiovascular diseases like hypertension (systolic blood pressure more than 130 and/or diastolic blood pressure more than 85 mm/Hg in at least three different occasions, diabetes (fasting plasma glucose level >126 mg/dl and/or a casual plasma glucose >200 mg/dl and/or HbA1C more than 6.5.

We excluded also patients with valvular and ischemic heart diseases, and patients who received prophylactic treatment for migraine, also we excluded patients with any contraindications to lacosamide.